Answers are grounded in this paper and cite their sources.
In tafamidis-treated ATTR-CM patients, initiation of dapagliflozin was well tolerated. The efficacy of SGLT2i therapy in patients with ATTR-CM needs to be studied in randomized controlled trials.
No takes yet. Share an insight, caveat, or question.
Dobner et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: